MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek, Chih Cheng Chen, Miklós Egyed, Martin Ellis, Laura Fox, Yeow T. Goh, Vikas Gupta, Claire Harrison, Jean Jacques Kiladjian, Mihaela C. Lazaroiu, Adam Mead, Donal McLornan, Mary F. McMullin, Stephen T. Oh, Andrew Perkins, Uwe Platzbecker, Christof Scheid, Alessandro Vannucchi, Sung Soo Yoon, Mark M. KowalskiRuben A. Mesa

Research output: Contribution to journalArticlepeer-review

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Original languageEnglish (US)
Pages (from-to)1449-1458
Number of pages10
JournalFuture Oncology
Volume17
Issue number12
DOIs
StatePublished - Apr 2021

Keywords

  • ACVR1
  • JAK inhibitor
  • Phase III clinical trial
  • anemia
  • danazol
  • hemoglobin
  • momelotinib
  • myelofibrosis
  • transfusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic'. Together they form a unique fingerprint.

Cite this